| [1] |
. J Exp Clin Cancer Res，2019，38（1）：268.
|
| [2] |
Chen DS，Mellman I. Oncology meets immunology：the cancer-immunity cycle［J］. Immunity，2013，39（1）：1-10.
|
| [3] |
Li QQ，Shi ZQ，Zhang F，et al. Symphony of nanomaterials and immunotherapy based on the cancer-immunity cycle［J］. Acta Pharm Sin B，2022，12（1）：107-134.
|
| [4] |
Starzer AM，Preusser M，Berghoff AS. Immune escape mechanisms and therapeutic approaches in cancer：the cancer-immunity cycle［J］. Ther Adv Med Oncol，2022，14：17588359221096219.
|
| [5] |
Schlake T，Thess A，Thran M，et al. mRNA as novel technology for passive immunotherapy［J］. Cell Mol Life Sci，2019，76（2）：301-328.
|
| [6] |
Ma S，Li XC，Wang XY，et al. Current progress in CAR-T cell therapy for solid tumors［J］. Int J Biol Sci，2019，15（12）：2548-2560.
|
| [7] |
Chen LP，Han X. Anti-PD-1/PD-L1 therapy of human cancer：past，present，and future［J］. J Clin Invest，2015，125（9）：3384-3391.
|
| [8] |
Saxena M，van der Burg SH，Melief CJM，et al. Therapeutic cancer vaccines［J］. Nat Rev Cancer，2021，21（6）：360-378.
|
| [9] |
Yu MH，Yang W，Yue WW，et al. Targeted cancer immunotherapy：nanoformulation engineering and clinical translation［J］. Adv Sci （Weinh），2022，9（35）：e2204335.
|
| [10] |
Liu ZG，Jiang W，Nam J，et al. Immunomodulating nanomedicine for cancer therapy［J］. Nano Lett，2018，18（11）：6655-6659.
|
| [11] |
Francis MJ. Recent advances in vaccine technologies［J］. Vet Clin North Am Small Anim Pract，2018，48（2）：231-241.
|
| [12] |
Davodabadi F，Sarhadi M，Arabpour J，et al. Breast cancer vaccines：new insights into immunomodulatory and nano-therapeutic approaches［J］. J Control Release，2022，349：844-875.
|
| [13] |
Mi Y，4th Hagan CT，Vincent BG，et al. Emerging nano-/ microapproaches for cancer immunotherapy［J］. Adv Sci （Weinh），2019，6（6）：1801847.
|
| [14] |
Chen J，Fang HP，Hu YY，et al. Combining mannose receptor mediated nanovaccines and gene regulated PD-L1 blockade for boosting cancer immunotherapy［J］. Bioact Mater，2022，7：167-180.
|
| [15] |
Zhou L，Hou B，Wang DG，et al. Engineering polymeric prodrug nanoplatform for vaccination immunotherapy of cancer［J］. Nano Lett，2020，20（6）：4393-4402.
|
| [16] |
Yang R，Xu J，Xu LG，et al. Cancer cell membrane-coated adjuvant nanoparticles with mannose modification for effective anticancer vaccination［J］. ACS Nano，2018，12（6）：5121-5129.
|
| [17] |
Lim JP，Gleeson PA. Macropinocytosis：an endocytic pathway for internalising large gulps［J］. Immunol Cell Biol，2011，89（8）：836-843.
|
| [18] |
Yang C，Zhang F，Chen FM，et al. Biomimetic nanovaccines potentiating dendritic cell internalization via CXCR4-mediated macropinocytosis［J］. Adv Healthc Mater，2023，12（5）：e2202064.
|
| [19] |
Guo JF，Zou YF，Huang L. Nano delivery of chemotherapeutic ICD inducers for tumor immunotherapy［J］. Small Methods，2023：e2201307.
|
| [20] |
Li YH，Liu XH，Zhang X，et al. Immunogenic cell death inducers for enhanced cancer immunotherapy［J］. Chem Commun，2021，57（91）：12087-12097.
|
| [21] |
Banstola A，Poudel K，Kim JO，et al. Recent progress in stimuli-responsive nanosystems for inducing immunogenic cell death［J］. J Control Release，2021，337：505-520.
|
| [22] |
Zhou JY，Wang GY，Chen YZ，et al. Immunogenic cell death in cancer therapy：present and emerging inducers［J］. J Cell Mol Med，2019，23（8）：4854-4865.
|
| [23] |
Song L，Hao Y，Wang CJ，et al. Liposomal oxaliplatin prodrugs loaded with metformin potentiate immunotherapy for colorectal cancer［J］. J Control Release，2022，350：922-932.
|
| [24] |
Qiu XY，Qu Y，Guo BB，et al. Micellar paclitaxel boosts ICD and chemo-immunotherapy of metastatic triple negative breast cancer［J］. J Control Release，2022，341：498-510.
|
| [25] |
Liang RJ，Liu LL，He HM，et al. Oxygen-boosted immunogenic photodynamic therapy with gold nanocages@manganese dioxide to inhibit tumor growth and metastases［J］. Biomaterials，2018，177：149-160.
|
| [26] |
Li W，Yang J，Luo LH，et al. Targeting photodynamic and photothermal therapy to the endoplasmic reticulum enhances immunogenic cancer cell death［J］. Nat Commun，2019，10（1）：3349.
|
| [27] |
Emens LA，Silverstein SC，Khleif S，et al. Toward integrative cancer immunotherapy：targeting the tumor microenvironment［J］. J Transl Med，2012，10：70.
|
| [28] |
Cao J，Yan Q. Cancer epigenetics，tumor immunity，and immunotherapy［J］. Trends Cancer，2020，6（7）：580-592.
|
| [29] |
Xiang XN，Wang JG，Lu D，et al. Targeting tumor-associated macrophages to synergize tumor immunotherapy［J］. Signal Transduct Target Ther，2021，6（1）：75.
|
| [30] |
Han SL，Wang WJ，Wang SF，et al. Tumor microenvironment remodeling and tumor therapy based on M2-like tumor associated macrophage-targeting nano-complexes［J］. Theranostics，2021，11（6）：2892-2916.
|
| [31] |
Liaw K，Reddy R，Sharma A，et al. Targeted systemic dendrimer delivery of CSF-1R inhibitor to tumor-associated macrophages improves outcomes in orthotopic glioblastoma［J］. Bioeng Transl Med，2021，6（2）：e10205.
|
| [32] |
Zhao Y，Rahmy S，Liu ZM，et al. Rational targeting of immunosuppressive neutrophils in cancer［J］. Pharmacol Ther，2020，212：107556.
|
| [33] |
Zhang YT，Guoqiang L，Sun MM，et al. Targeting and exploitation of tumor-associated neutrophils to enhance immunotherapy and drug delivery for cancer treatment［J］. Cancer Biol Med，2020，17（1）：32-43.
|
| [34] |
Que HY，Fu QM，Lan TX，et al. Tumor-associated neutrophils and neutrophil-targeted cancer therapies［J］. Biochim Biophys Acta Rev Cancer，2022，1877（5）：188762.
|
| [35] |
Tang LG，Wang ZT，Mu QC，et al. Targeting neutrophils for enhanced cancer theranostics［J］. Adv Mater，2020，32（33）：e2002739.
|
| [36] |
Mao XQ，Xu J，Wang W，et al. Crosstalk between cancer-associated fibroblasts and immune cells in the tumor microenvironment：new findings and future perspectives［J］. Mol Cancer，2021，20（1）：131.
|
| [37] |
Panagi M，Mpekris F，Chen PW，et al. Polymeric micelles effectively reprogram the tumor microenvironment to potentiate nano-immunotherapy in mouse breast cancer models［J］. Nat Commun，2022，13（1）：7165.
|
| [38] |
Tan YN，Huang JD，Li YP，et al. Near-infrared responsive membrane nanovesicles amplify homologous targeting delivery of anti-PD immunotherapy against metastatic tumors［J］. Adv Healthc Mater，2022，11（6）：e2101496.
|
| [39] |
Tang XY，Luo ZL，Xiong YL，et al. The proliferative role of immune checkpoints in tumors：double regulation［J］. Cancers，2022，14（21）：5374.
|
| [40] |
Archilla-Ortega A，Domuro C，Martin-Liberal J，et al. Blockade of novel immune checkpoints and new therapeutic combinations to boost antitumor immunity［J］. J Exp Clin Cancer Res，2022，41（1）：62.
|
| [41] |
Yang L，Pang YL，Moses HL. TGF-β and immune cells：an important regulatory axis in the tumor microenvironment and progression［J］. Trends Immunol，2010，31（6）：220-227.
|
| [42] |
Liu M，Wang X，Wang L，et al. Targeting the IDO1 pathway in cancer：from bench to bedside［J］. J Hematol Oncol，2018，11（1）：100.
|
| [43] |
Haist M，Mail?nder V，Bros M. Nanodrugs targeting T cells in tumor therapy［J］. Front Immunol，2022，13：912594.
|
| [44] |
Xue S，Hu M，Iyer V，et al. Blocking the PD-1/PD-L1 pathway in glioma：a potential new treatment strategy［J］. J Hematol Oncol，2017，10（1）：81.
|
| [45] |
Gao Y，Ouyang ZJ，Yang C，et al. Overcoming T cell exhaustion via immune checkpoint modulation with a dendrimer-based hybrid nano complex［J］. Adv Healthc Mater，2021，10（19）：e2100833.
|
| [46] |
Yang GX，Zhou D，Dai Y，et al. Construction of PEI-EGFR-PD-L1-siRNA dual functional nano-vaccine and therapeutic efficacy evaluation for lung cancer［J］. Thorac Cancer，2022，13（21）：2941-2950.
|
| [47] |
Huo JL，Wang YT，Fu WJ，et al. The promising immune checkpoint LAG-3 in cancer immunotherapy：from basic research to clinical application［J］. Front Immunol，2022，13：956090.
|
| [48] |
Wan WJ，Huang G，Wang Y，et al. Coadministration of iRGD peptide with ROS-sensitive nanoparticles co-delivering siFGL1 and siPD-L1 enhanced tumor immunotherapy［J］. Acta Biomater，2021，136：473-484.
|
| [49] |
Selvan SR，Dowling JP，Kelly WK，et al. Indoleamine 2，3-dioxygenase （IDO）：biology and target in cancer immunotherapies［J］. Curr Cancer Drug Targets，2016，16（9）：755-764.
|
| [50] |
Mei KC，Liao YP，Jiang JH，et al. Liposomal delivery of mitoxantrone and a cholesteryl indoximod prodrug provides effective chemo-immunotherapy in multiple solid tumors［J］. ACS Nano，2020，14（10）：13343-13366.
|
下载:
